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ABSTRACT
Objective: To systematically review studies reporting
the prevalence in general adult inpatient populations of
foot disease disorders (foot wounds, foot infections,
collective ‘foot disease’) and risk factors (peripheral
arterial disease (PAD), peripheral neuropathy (PN), foot
deformity).
Methods: A systematic review of studies published
between 1980 and 2013 was undertaken using
electronic databases (MEDLINE, EMBASE and
CINAHL). Keywords and synonyms relating to
prevalence, inpatients, foot disease disorders and
risk factors were used. Studies reporting foot disease
or risk factor prevalence data in general inpatient
populations were included. Included study’s reference
lists and citations were searched and experts
consulted to identify additional relevant studies.
2 authors, blinded to each other, assessed the
methodological quality of included studies.
Applicable data were extracted by 1 author and
checked by a second author. Prevalence proportions
and SEs were calculated for all included studies.
Pooled prevalence estimates were calculated using
random-effects models where 3 eligible studies
were available.
Results: Of the 4972 studies initially identified, 78
studies reporting 84 different cohorts (total
60 231 517 participants) were included. Foot disease
prevalence included: foot wounds 0.01–13.5% (70
cohorts), foot infections 0.05–6.4% (7 cohorts),
collective foot disease 0.2–11.9% (12 cohorts). Risk
factor prevalence included: PAD 0.01–36.0% (10
cohorts), PN 0.003–2.8% (6 cohorts), foot deformity
was not reported. Pooled prevalence estimates were
only able to be calculated for pressure ulcer-related
foot wounds 4.6% (95% CI 3.7% to 5.4%)), diabetes-
related foot wounds 2.4% (1.5% to 3.4%),
diabetes-related foot infections 3.4% (0.2% to 6.5%),
diabetes-related foot disease 4.7% (0.3% to 9.2%).
Heterogeneity was high in all pooled estimates
(I2=94.2–97.8%, p<0.001).
Conclusions: This review found high heterogeneity,
yet suggests foot disease was present in 1 in every 20
inpatients and a major risk factor in 1 in 3 inpatients.
These findings are likely an underestimate and more
robust studies are required to provide more precise
estimates.
INTRODUCTION
Foot disease is a common result of the patho-
physiology of chronic conditions.1–6 Foot
disease disorders have been reported to be
present in signiﬁcant numbers of people hos-
pitalised throughout the world.1–6 The pres-
ence of foot disease disorders in those
hospitalised has also been associated with
extended hospital stays,1–5 amputations,1–3 6–9
institutionalisation,10 11 high mortality
rates1 2 7 12 and signiﬁcant ongoing health-
care needs.1 2 6 13 14
Foot disease is a term typically used to
denote severe foot-related disorders that are
likely to result in hospitalisation and amputa-
tion and most commonly refers to foot
wounds and foot infections.1 2 12–14 However,
‘foot disease’ is also commonly used as a
catchall term that collectively includes foot
wounds, foot infection and other less
common severe foot-related disorders, such
as critical ischaemia, and Charcot neuroar-
thropathy.1 2 12–14 The major risk factors for
foot disease include peripheral arterial
disease (PAD), peripheral neuropathy (PN)
and foot deformity.1 2 5 6 12–16 However, these
risk factors can also become foot disease
Strengths and limitations of this study
▪ This is the first systematic review and
meta-analysis to investigate the prevalence of
foot disease in general inpatient populations.
▪ A broad search strategy was used to minimise
the risk of missing relevant studies.
▪ One author extracted data; however, this was
checked by a second author.
▪ Studies reporting foot disease and risk factor
prevalence in inpatient populations had high het-
erogeneity and thus pooled estimates should be
interpreted with caution.
▪ Very few studies reported foot disease or risk
factor data as the primary study outcome and
most are likely to have under-reported.
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disorders if severe and result in hospitalisation or ampu-
tation.1 2 5 6 12–16 Foot disease disorders and risk factors
typically result from chronic conditions,3 5–9 such as dia-
betes,1 2 7–9 11–14 cardiovascular disease,10 17–19 chronic
kidney disease6 15 20 and cancer.7 8 21
Studies investigating the presence of foot disease in
hospital inpatients have predominantly focused within
discrete inpatient populations, such as only geriatric or
patients with diabetes.1 2 5 11 14 20 22 23 Fewer studies
have reported the prevalence of foot disease across
more representative general inpatient populations that
include the diverse range of people typically hospitalised
at any one time.4 24 Thus, precise estimates of the preva-
lence of foot disease in general inpatient populations
are unknown.4 24 Furthermore, there have been no
known systematic reviews investigating the prevalence of
foot disease in inpatient populations. In order for clini-
cians, researchers and policymakers to begin to quantify,
understand and address the burden that foot disease
imposes on inpatient care, it seems necessary to deter-
mine the foot disease prevalence in general inpatient
populations rather than discrete segments of the
inpatient population.
The primary aim of this study was to systematically
review all studies reporting the prevalence in general
adult inpatient populations of foot disease disorders
(foot wounds, foot infections and collective ‘foot
disease’) and risk factors (PAD, PN and foot deformity).
Secondary aims were to determine the pooled preva-
lence estimates for each foot disease disorder and risk
factor, and investigate the prevalence of amputations
from included studies.
METHODS
The authors have adhered to the PRISMA guideline
reporting checklist (see online supplementary table S1)
and PRISMA ﬂow diagram (see ﬁgure 1).25
Search strategy
Electronic databases (MEDLINE, EMBASE and
CINAHL) were systematically searched by the ﬁrst
author (PAL) for all studies published between 1980
and 2013 reporting the prevalence of foot disease disor-
ders or risk factors in an inpatient population. The year
1980 was chosen due to the advent of validated outcome
measures to investigate foot disease disorders at this
time.26 27 The search strategy included broad keywords
and synonyms combining the anatomical area (eg, foot);
disease (eg, wounds, infection) or risk factors (eg, PAD,
PN); populations (eg, inpatients); and epidemiological
terms (eg, prevalence) of interest. See online supple-
mentary table S2 for the full search syntax with trunca-
tion used for the electronic database search.
Figure 1 Search strategy and study selection results.
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Study selection
All unique study abstracts identiﬁed were screened by
the ﬁrst author (PAL) using an overarching initial screen-
ing question: Does the article appear to discuss original ﬁnd-
ings on the prevalence of foot disease or risk factors within adult
populations staying overnight in a hospital? The full text was
sought if it appeared to address the screening question.
A detailed eligibility assessment was then undertaken
by the ﬁrst author (PAL) for ﬁnal inclusion. Studies
were eligible for inclusion if they met all of the below
inclusion criteria and did not meet any exclusion cri-
teria. Inclusion criteria were studies:
▸ Indexed in the aforementioned electronic databases;
▸ Published in peer-reviewed academic journals;
▸ Available in full text;
▸ Written in the English language;
▸ Reporting a study population representative of a
general adult inpatient population. General adult
inpatient populations were deﬁned as reporting all
eligible participants from at least one general medical
or surgical hospital inpatient ward; and
▸ Reporting the number, or proportion, of a foot
disease disorder or risk factor. Foot disease disorders
(foot wound, foot infection or collective ‘foot
disease’) and risk factors (PAD, PN or foot deformity)
were deﬁned as listing of the foot disease disorder or
risk factor concerned (or a synonym) in the study.
Thus, no speciﬁc diagnostic criteria were used and
reporting could have been elicited from a range of
self-report, medical record audit or clinical examin-
ation methods. ‘Foot disease’ was deﬁned as the col-
lective reporting of foot wounds, foot infections and
other severe foot-related disorders together.
However, studies were excluded if they met any of the
following exclusion criteria:
▸ Studies reporting designs that were primarily case
studies, literature reviews, case–control, validity or
reliability studies; and
▸ Studies reporting a study population that was not
deﬁned as representative of a general adult hospital
inpatient population; including studies investigating
primarily children (<18 years), outpatients, geriatric
inpatients (>65 years), long-term care inpatients or
discrete condition-related inpatients (such as only
patients with diabetes).
At completion of the search strategy and study selec-
tion, the ﬁrst author (PAL) hand searched the reference
lists of all included studies and citation searched
(Scopus) all studies citing the included studies.
Following this process it became apparent that all rele-
vant studies had been identiﬁed, with the notable excep-
tion of pressure ulcers on very speciﬁc anatomical
locations of the foot, such as the heel or ankle. Thus, an
additional search was conducted for all studies reporting
only the prevalence of pressure ulcers in inpatient popu-
lations using a similar search strategy (see online supple-
mentary table S2). The hand searching of references
lists and citation search process was repeated for any
additional identiﬁed included studies from this add-
itional search. Lastly, the authors consulted six external
content experts (eg, physicians, surgeons, nurses, podia-
trists) in the ﬁeld. The authors forwarded the systematic
review abstract, search terms and a list of all identiﬁed
included studies to the content experts, and content
experts provided any additional study titles they consid-
ered may have also met the inclusion criteria.
Quality assessment
A study quality assessment tool was used to perform the
study quality assessments of all included studies.28 This
tool was originally designed to assess the methodological
quality of pressure ulcer prevalence in inpatient popula-
tions.28 The authors made minor modiﬁcations to this
tool to reﬂect the focus of foot disease rather than pres-
sure ulcers. See online supplementary table S3 for the
modiﬁed 10-item questions used to evaluate the meth-
odological quality of studies included in this review. Each
item was scored either as a ‘yes’ (score=1) or ‘no/not
reported’ (score=0) with a total possible score of 10.28
Two authors (PAL and MEF), blinded to each other’s
assessments, assessed the methodological quality of all
included studies using the aforementioned tool.
A research assistant independent of the authors
redacted all identifying features (title, authors and
journal details) of all included studies prior to forward-
ing studies in a random order to the authors individually
for assessment. At the conclusion of this process, the
overall agreement between the two blinded author’s
scores was calculated and reported for all items. Any dif-
ferences in the original blinded assessments between the
two authors (PAL and MEF) were then resolved by con-
sensus agreement between the two authors. A third
author (SEH) was used to make a ﬁnal adjudication if
agreement could not be reached. Studies were given a
total study quality score which was classiﬁed as either
‘poor’ (total score=0–3), ‘moderate’ (total score=4–6) or
‘good’ (total score=7–10) study quality.
Data extraction
Data extraction was completed for each included study
by the ﬁrst author (PAL) using a custom-designed data
extraction spreadsheet. Data were extracted for total
sample size, average age (mean or median), age range,
proportion of males, and any numbers or prevalence
data for the foot disease or risk factor variables. Sample
size data were also extracted on condition-speciﬁc sub-
groups (diabetes or pressure ulcers) and amputations if
reported. All extracted data were then checked for
accuracy and omissions by a non-blinded second author
(SDJ). At the conclusion of this data extracting checking
process, the overall agreement between the second
checking author’s ﬁndings (SDJ) and the original
author’s ﬁndings (PAL) was calculated and reported.
Any differences in the data extraction ﬁnding between
the two authors (PAL and SDJ) were then resolved by
consensus agreement between the two authors (PAL
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and SDJ). A third author (SEH) was used to make a
ﬁnal adjudication if agreement could not be reached.
Statistical analysis
Data were analysed using Stata V.13 (StataCorp LP,
College Station, Texas, USA) and Microsoft Excel V.2010
(Microsoft Corporation, Redmond, Washington, USA).
Descriptive statistics were reported on all included
studies. Medians (IQRs) were calculated for the study
quality scores of groups of studies using similar study
design and reporting the same foot disease disorder or
risk factor. Kruskal-Wallis and Mann-Whitney U tests
were used to test study quality score differences between
these groups. For the purposes of measures of agree-
ment between authors, a percentage agreement and κ
statistic were used.29 The κ value (SEs) strengths of
agreement were categorised as: no agreement<0;
slight agreement=0–0.20; fair agreement=0.21–0.40;
moderate agreement=0.41–0.6; substantial agreement=
0.61–0.8; and near-perfect agreement=0.81–1.0.29
The summary statistic used for each study’s foot disease
disorder or risk factor variable was a prevalence propor-
tion. The SE for each prevalence estimate was then calcu-
lated. If a study only reported numbers, these numbers
were converted to a prevalence proportion using the
ratio of the number of individuals with the foot disease
disorder or risk factor variable reported (numerator)
and the number of the total sample size of the study
(denominator). Studies reporting only numbers of a foot
disease disorder or risk factor per total disorder (eg, foot
wounds per total wounds) were converted to numbers of
patients with the foot disease disorder or risk factor for
the purpose of this review. This was performed using the
ratio of the number of the foot disease disorder or risk
factor and the number of total disorder, multiplied by
the total sample size population. These studies were
excluded from any meta-analyses performed.
Meta-analyses were calculated where three or more
studies of at least ‘moderate’ methodological quality had
reported the same foot disease disorder or risk factor
using a similar study design.29 Meta-analyses were used
to calculate pooled prevalence estimates for the foot
disease disorder or risk factor using a random-effects
model.29 Random effects were used to give an average
estimate across heterogeneous studies weighted on total
sample size.29 The I2 test was used to test for heterogen-
eity across studies included in individual meta-analysis; I2
values of <25%, 25–75% and >75% were rated as low,
moderate and high heterogeneity, respectively.29
Scatterplots were used to investigate if individual
meta-analysis prevalence estimates were inﬂuenced by
factors, such as sample size or study quality.29
RESULTS
Search results
Figure 1 displays the search strategy and study selection
results. The search strategy yielded a total of 4972
unique records of which 698 studies were retrieved for
detailed eligibility assessment. Of those, 56 studies met
the eligibility criteria and were included. An additional
306 potentially eligible articles were identiﬁed from
hand searching references and citation searching pro-
cesses from the 56 included studies and 22 of those met
eligibility criteria and were included. Lastly, 30 further
additional studies were identiﬁed by the external
content experts and none of those met the eligibility cri-
teria. Overall, 78 studies, reporting 84 individual hospital
cohorts, were included in this systematic review.
Study characteristics
Table 1 displays the summary characteristics of the 84
individual study cohorts from the 78 included studies.
Online supplementary tables S4–6 display the speciﬁc
individual characteristics and citations for each of the 84
individual study cohorts. Rather than presenting tables in
alphabetical order, the authors chose to group similar
studies together for ease of comparison. Study cohorts
were grouped according to the foot disease disorder or
risk factor reported and study design (prospective or
retrospective) used due to the reported prevalence dif-
ferences ascertained from different foot disease disor-
ders, risk factors and study designs.30 31
The 84 included study cohorts included a total of
60 231 517 participants; 66 (79%) prospective cohorts
reported on a total of 643 141 participants and 18
(21%) retrospective cohorts reported on a total of
59 588 376 participants (table 1). Sample sizes ranged
from 59 to 57 639 000, 59 to 158 236 in prospective
studies and 167 to 57 539 000 in retrospective studies.
Only 15 (18%) included study cohorts were investigated
for foot disease disorders or risk factors as the primary
aim of the study; 8 in prospective cohorts and 7 in retro-
spective cohorts. Study cohorts reporting foot disease
disorders included: 70 (83%) foot wounds, 7 (8%) foot
infection and 12 (14%) reported foot disease collect-
ively. Study cohorts reporting risk factors included: 10
(12%) PAD, 6 (7%) PN and no studies reported foot
deformity. Study cohorts could be grouped into three
distinct subgroups of condition-related studies, includ-
ing: 8 (10%) reporting all-cause foot disease disorders
or risk factors (see online supplementary table S4), 24
(29%) reporting diabetes-related foot disease disorders
or risk factors (see online supplementary table S5), and
52 (62%) reporting pressure ulcer-related foot disease
disorders or risk factors (see online supplementary
table S6) in their general inpatient population sample.
Three studies reported both all-cause and diabetes-
related foot disease disorders or risk factor prevalence in
their general inpatient population sample.
Quality assessment
Online supplementary table S7 displays the original
methodological quality assessments from the two
blinded authors for the 78 included studies. The κ (SE)
values calculated between the two blinded author’s
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assessments ranged from 0.69 (0.10) to 0.96 (0.04)
which corresponded to ‘substantial’ or ‘near-perfect’
strengths of agreement for each item analysed. The per-
centage agreements between the two blinded author’s
assessments ranged between 86% and 99% with an
overall agreement of 92% (720 of the 780 total items).
Table 2 displays the ﬁnal agreed methodological quality
assessment results for all included studies. Overall, 25
(32%) studies had ‘good’ methodological study quality
scores, 40 (51%) had ‘moderate’ study quality scores
and 13 (17%) had ‘poor’ study quality scores.
Table 1 displays differences in median study quality
scores between studies reporting different study designs
and different condition-related foot disease disorders or
risk factors. Prospective studies reported statistically
signiﬁcant higher study quality scores (median (IQR)
6(5–7)) than retrospective studies (3(3–5); p<0.05).
Studies reporting pressure ulcer-related foot disease or
risk factors also reported statistically signiﬁcant higher
study quality scores (7(5–8)) than those reporting all-
cause foot disease or risk factors (5(4.5–6)) or diabetes
foot-related foot disease or risk factors (4(3–5);
(p<0.05). Table 2 displays the ﬁndings from the assess-
ment of all 10 individual methodological quality items
used. These ﬁndings revealed: 83% of studies reported a
prospective design, 83% reported an appropriately
sampled population, 88% recruited an adequate sample
size (>300 participants), 68% used a physical examin-
ation to determine the foot disease disorder or risk
factor, 67% used a validated outcome measure and 60%
had an adequate response rate of eligible participants. It
also revealed: only 22% reported measuring the foot
disease disorder or risk factor in an unbiased manner
and 0% reported foot disease or risk factor prevalence
estimates with CIs.
Data extraction
Overall percentage agreement between the ﬁndings of
the two authors performing data extraction was 97%
(720 of the 740 total items). The 20 differences between
the second author (SDJ) checking the data extraction
ﬁndings of the ﬁrst author (PAL) included: eight round-
ing, eight data entry and four case deﬁnition errors. All
20 differences were errors originally made in the data
extraction process by the ﬁrst author (PAL). Table 1 and
online supplementary tables S4–6 display the ﬁnal
agreed consensus ﬁndings from the data extraction
process for all included studies.
Prevalence of foot disease disorders and risk factors
Table 1 reports the total and subgroups of condition-
related foot disease disorders and risk factor prevalence
ranges in general inpatient populations. Total foot
disease disorder prevalence ranges included: 0.01–
13.5% for foot wounds, 0.05–6.4% for foot infections
and 0.2–11.9% for collective foot disease. Total risk
factor prevalence ranges included: 0.01–36.0% for PAD,
0.003–2.8% for PN and foot deformity was not reported.
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Table 2 Final agreed methodological quality assessment results for all included studies*
Author Year
Question
1
Question
2
Question
3
Question
4
Question
5
Question
6
Question
7
Question
8
Question
9
Question
10
Total
score†
Quality
category‡
All-cause
Antonopoulos32 2005 0 1 1 1 1 0 0 0 1 1 6 Moderate
Currie24 1998 1 0 0 1 0 0 1 0 1 1 5 Moderate
Donnan33 2000 1 0 0 1 0 0 1 0 1 1 5 Moderate
Gottrup34 2013 1 1 0 1 0 0 0 0 0 0 3 Poor
Gruen35 1997 1 1 1 1 0 0 1 0 0 1 6 Moderate
Henke36 2005 1 0 0 1 0 0 1 0 1 0 4 Moderate
Lacroix37 2008 1 1 1 0 1 1 1 0 1 1 8 Good
Morgan38 2010 1 0 0 1 0 0 1 0 1 1 5 Moderate
Diabetes-related
Ajayi39 2009 0 0 0 1 0 0 1 0 0 1 3 Poor
Asumanu40 2010 0 1 1 1 1 0 0 0 1 0 5 Moderate
Chijioke41 2010 0 0 0 1 0 0 1 0 1 0 3 Poor
Daultry42 2011 1 1 1 1 0 0 0 0 0 0 4 Moderate
Hurd43 2009 1 1 1 1 1 0 1 0 0 0 6 Moderate
Leichter44 1982 0 0 0 1 0 0 1 0 0 0 2 Poor
Mahe45 2006 1 1 1 1 0 0 1 0 0 1 6 Moderate
Masson46 1992 1 1 0 1 0 0 1 0 0 0 4 Moderate
Mohammad
Akther47
2011 0 1 1 1 1 0 0 0 1 0 5 Moderate
Mottini48 2003 0 0 0 1 0 0 1 0 0 0 2 Poor
Nason49 2013 1 0 0 1 0 0 1 0 0 0 3 Poor
Ogbera50 2006 1 0 0 1 0 0 1 0 0 0 3 Poor
Ogbera51 2007 0 1 0 1 0 0 1 0 0 1 4 Moderate
Otu52 2013 0 0 0 1 1 0 1 0 1 0 4 Moderate
Sjoberg53 2007 0 0 0 1 0 0 1 0 0 1 3 Poor
Tait54 2007 1 1 0 1 0 0 0 0 0 0 3 Poor
Unachukwu55 2007 0 1 1 1 1 0 0 0 0 0 4 Moderate
Wallymahmed56 2005 1 1 0 1 0 0 1 0 0 0 4 Moderate
Williams57 1985 1 0 0 1 0 0 1 0 0 0 3 Poor
Pressure ulcer-related
Alja’afreh58 2013 0 1 1 0 0 0 0 0 0 0 2 Poor
Allcock59 1994 1 1 1 1 0 0 1 0 0 0 5 Moderate
Amlung60 2001 1 1 1 1 1 0 0 0 0 0 5 Moderate
Barczak61 1997 1 1 1 1 1 0 0 0 0 1 6 Moderate
Barrois62 1995 1 1 0 1 1 0 0 0 0 1 5 Moderate
Barrois63 2008 1 1 0 1 1 0 1 0 1 1 7 Good
Bours64 1999 1 1 1 1 1 1 0 0 0 1 7 Good
Bours65 2002 1 1 1 1 1 1 0 0 0 1 7 Good
Brito66 2013 1 1 1 1 1 0 0 0 0 1 6 Moderate
Charlier67 2001 1 1 1 0 0 0 1 0 0 1 5 Moderate
Clark68 1992 1 1 0 1 1 0 1 0 0 0 5 Moderate
Cole69 2004 1 1 1 0 1 0 1 0 0 0 5 Moderate
da Silva
Cardoso70
2010 1 1 1 1 1 0 0 0 0 0 5 Moderate
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Table 2 Continued
Author Year
Question
1
Question
2
Question
3
Question
4
Question
5
Question
6
Question
7
Question
8
Question
9
Question
10
Total
score†
Quality
category‡
Dealey71 1991 1 1 0 1 0 0 0 0 0 0 3 Poor
Dealey72 1994 1 1 1 1 1 0 1 0 0 0 6 Moderate
Ek73 1982 1 1 0 1 0 0 0 0 0 0 3 Poor
Gallagher74 2008 1 1 1 1 1 1 1 0 0 1 8 Good
Galvan-
Martinez75
2012 1 1 1 0 1 1 1 0 0 1 7 Good
Gawron76 1994 1 1 1 1 1 1 1 0 0 1 8 Good
Gethin77 2005 1 1 1 1 1 0 1 0 0 1 7 Good
Gosnell78 1992 1 1 1 1 1 1 1 0 1 0 8 Good
Groeneveld79 2004 1 1 1 1 1 1 1 0 0 1 8 Good
Gunningberg80 2005 1 1 1 1 1 1 1 0 0 1 8 Good
Gunningberg81 2006 1 1 1 1 1 1 1 0 0 1 8 Good
Gunningberg82 2008 1 1 1 1 1 1 1 0 0 1 8 Good
Gunningberg83 2013 1 1 1 1 1 0 0 0 0 1 6 Moderate
Hopkins84 2000 1 1 1 1 1 0 0 0 0 0 5 Moderate
House85 2011 1 1 1 0 1 0 0 0 0 0 4 Moderate
Inan86 2012 1 1 1 1 1 0 1 0 1 1 8 Good
Jenkins87 2010 1 1 1 1 1 0 0 0 0 0 5 Moderate
Lahmann88 2006 1 1 1 1 1 0 1 0 0 1 7 Good
Langemo89 1990 1 1 1 0 1 0 0 0 0 0 4 Moderate
Lepisto90 2001 1 1 1 0 1 0 0 0 0 0 4 Moderate
Meehan91 1990 1 1 1 1 1 0 0 0 1 0 6 Moderate
Meehan92 1994 1 1 1 1 1 0 0 0 1 0 6 Moderate
Nyquist93 1987 1 1 1 1 1 0 0 0 0 0 5 Moderate
O’Brien94 1998 1 1 1 1 1 0 0 0 0 0 5 Moderate
Pearson95 2000 1 1 1 1 1 0 1 0 0 0 6 Moderate
Soldevilla96 2006 1 1 0 1 1 0 1 0 0 0 5 Moderate
Thoroddsen97 1999 0 1 0 1 1 1 1 0 0 1 6 Moderate
Tubaishat98 2011 1 1 1 1 1 1 1 0 0 1 8 Good
Tubaishat99 2013 1 1 1 0 1 1 1 0 0 1 7 Good
Uzun100 2007 1 1 1 1 1 0 1 0 1 1 8 Good
Vanderwee101 2007 1 1 1 1 1 1 0 0 0 1 7 Good
Vanderwee102 2011 1 1 1 1 1 1 0 0 1 1 8 Good
Vangilder4 2008 1 1 1 1 1 0 0 0 1 1 7 Good
Vangilder103 2010 1 1 1 1 1 0 0 0 1 1 7 Good
Wann-
Hansson104
2008 1 1 1 1 1 0 1 0 1 1 8 Good
Whittington105 2004 1 1 1 1 0 0 0 0 0 0 4 Moderate
Young106 2002 1 1 1 1 1 1 1 0 0 1 8 Good
Zhao107 2010 1 1 1 1 1 0 1 0 0 1 7 Good
Total (n) 65 65 53 69 52 17 46 0 20 39 426
Total (%) 83.3 83.3 67.9 88.5 66.7 21.8 60.0 0 25.6 50.0 54.6
*Please see online supplementary table S3 for descriptions of each question; score: 1, ‘yes’; 0, ‘no’ or ‘not reported’.
†Total score, total agreed study quality score from the methodological assessment performed (total possible score is 10).
‡Quality category, total study quality score was classified as either ‘poor’ (total score=0–3), ‘moderate’ (total score=4–6) or ‘good’ (total score=7–10) study quality score.
Author, primary author of included study; Year, year included study was published.
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Amputation prevalence ranges were 0.03–1.5%. The
prevalence ranges were different for subgroups of
condition-related foot disease disorders and risk factors
reported. Prevalence ranges for foot wounds included:
0.7–4.2% for all-cause foot wounds; 0.01–7.0% for
diabetes-related foot wounds and 0.3–13.5% for pressure
ulcer-related foot wounds. Prevalence ranges for foot
infections included: 0.09–0.5% for all-cause foot infec-
tion, 0.05–6.4% for diabetes-related foot infections and
pressure ulcer-related foot infections was not reported.
Prevalence ranges for collective foot disease included:
0.2–1.2% for all-cause foot disease, 0.2–11.9% for
diabetes-related foot disease and pressure ulcer-related
foot infections was not reported. Prevalence ranges for
PAD included: 0.3–36.0% for all-cause PAD and 0.01–
0.4% for diabetes-related PAD. Prevalence ranges for PN
included: 0.2% for all-cause PN and 0.003–2.8% for
diabetes-related PN. Again prevalence was greater in pro-
spectively designed studies for all condition-related foot
disease or risk factors investigated in general inpatient
populations, with the exception of collective foot disease
and PN.
Meta-analyses
Four foot disease disorders met the prespeciﬁed
minimum for meta-analysis calculation of three eligible
studies with similar study designs. Tables 3–6 report the
pooled prevalence estimates from the meta-analyses cal-
culations for pressure ulcer-related foot wounds,
diabetes-related foot wounds, diabetes-related foot infec-
tions and diabetes-related foot disease. Table 3 reports a
pooled prevalence estimate for pressure ulcer-related
foot wounds based on 14 included studies reporting
sample sizes ranging from 60 to 37 307 and study quality
scores from 4 to 8. The pooled prevalence estimate was
4.6% (95% CI 3.7% to 5.4%, p<0.001; I2=95.3%,
p<0.001). Examination of scatterplots revealed a bias
between higher reported pressure ulcer-related foot
wound prevalence and those studies using an unbiased,
reliable outcome measure (ﬁgure S1).
Table 4 reports a pooled prevalence estimate for
diabetes-related foot wounds based on six included
studies reporting sample sizes ranging from 624 to 5188
and study quality scores from 4 to 6. The pooled preva-
lence estimate was 2.4% (95% CI 1.5% to 3.4%, p<0.001;
I2=94.2%, p<0.001). Examination of scatterplots revealed
sources of bias between higher reported diabetes-related
foot wound prevalence and those studies either report-
ing smaller sample sizes, having lower study quality or
studies conducted in developing countries (ﬁgure S2).
Table 5 reports a pooled prevalence estimate for
diabetes-related foot infections based on three included
studies reporting sample sizes ranging from 827 to 5188
and study quality scores from 4 to 5. The pooled preva-
lence estimate was 3.4% (95% CI 0.2% to 6.5%, p<0.05;
I2=97.0%, p<0.001). Scatterplots were not evaluated due
to the limited number of included studies.
Table 6 reports a pooled prevalence estimate for
diabetes-related foot disease based on three included
studies reporting sample sizes ranging from 810 to 5188
and study quality scores from 4 to 5. The pooled preva-
lence estimate was 4.7% (95% CI 0.3% to 9.2%, p<0.05;
I2=97.8%, p<0.001). Scatterplots were not evaluated due
to the limited number of included studies.
DISCUSSION
Principal findings
This study is the ﬁrst systematic review to investigate the
prevalence of foot disease in representative general
inpatient populations. The prevalence of foot disease
disorders in general inpatient populations ranged from
Table 3 Pooled random-effects estimates for pressure ulcer-related foot wound prevalence expressed as % (95% CI)
Study
Sample
size
Prevalence
estimates 95% CI
Percentage
weighting
Study quality
score
Barrois et al63 37 307 3.7 3.5 to 3.9 9.86 7
Brito et al66 473 4.7 2.8 to 6.5 6.59 6
Gallagher et al74 672 3.0 1.7 to 4.3 8.05 8
Gethin et al77 506 3.0 1.5 to 4.4 7.59 7
Gunningberg80 612 8.8 6.8 to 11.4 5.89 8
Gunningberg81 369 4.6 2.5 to 6.7 6.04 8
Gunningberg and Stotts82 632 6.5 4.6 to 8.4 6.53 8
Gunningberg et al83 16 466 6.7 6.3 to 7.1 9.71 6
House et al85 60 5.0 −0.5 to 10.5 1.88 4
Lahmann et al88 16 728 3.2 2.9 to 3.5 9.81 7
Tubaishat et al98 302 7.8 4.7 to 10.9 4.29 8
Tubaishat and Aljezawi99 295 3.0 1.1 to 4.9 6.54 7
Vanderwee et al101 5947 4.4 3.9 to 4.9 9.55 7
Wann-Hansson et al104 535 3.0 1.5 to 4.4 7.67 8
Pooled estimate 4.6 3.7 to 5.4 p<0.001
I2 95.3% p<0.001
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0% to 13%, while the prevalence of a major risk factor
for foot disease ranged from 0% to 36%. Meta-analyses
could only be calculated for four condition-related foot
disease disorders. These pooled prevalence estimates
indicated that 4.6% (95% CI 3.7% to 5.4%) of all inpati-
ents had a pressure ulcer present on their foot, 4.7%
(0.3% to 9.2%) had collective diabetes-related foot
disease, 2.4% (1.5% to 3.4%) had diabetes-related foot
wounds and 3.4% (0.2% to 6.5%) had diabetes-related
foot infections. Additional ﬁndings from this review sug-
gested up to 1.2% of all inpatients had been hospitalised
for the primary reason of foot disease. However, this sys-
tematic review also revealed large variations in reported
prevalence and study quality within each foot disease dis-
order or risk factor of interest. These variations appear
to have been the major contributors to the high statis-
tical heterogeneity reported in the pooled prevalence
estimates from this review.
Strengths and weaknesses
The ﬁndings of this systematic review should be viewed
in the context of several consistent limitations observed
in the included studies of this review. First, most
included studies reported foot disease disorders or risk
factor as an additional outcome and no included studies
reported CIs or sample size calculations for foot disease
ﬁndings. Second, most included studies reported a
condition-related (such as diabetes-related), rather than
an all-cause, foot disease disorder or risk factors in a
general inpatient population. Third, study quality scores
varied considerably depending on the study design and
foot disease disorder or risk factor investigated. Fourth,
all-cause and diabetes-related foot disease disorder or
risk factor ﬁndings were predominately reported from
retrospective studies. Lastly, while studies reporting pres-
sure ulcer-related foot disease were all prospective and
mostly of high quality, a large proportion reported only
pressure ulcers on the heel. Overall, these limitations
impact on the capture, precision and heterogeneity of
ﬁndings and indicate included studies are likely to have
under-reported foot disease disorder and risk factor
prevalence.
The authors are also cognisant of limitations in the
methodology used to perform this systematic review.
First, this review used broad inclusion criteria for foot
disease disorders, risk factors and general inpatient
population deﬁnitions, and this may have contributed
to the heterogeneity of ﬁndings. Second, the original
search strategy was performed by only one author and
did not initially identify studies reporting pressure ulcer-
related foot wounds on speciﬁc anatomical locations of
the foot. However, the authors believe this was
addressed by conducting a broad initial search strategy,
an extensive additional pressure ulcer-related search
strategy, hand searching references of all included
studies, citation searching all included studies and con-
tacting external content experts to identify any remain-
ing relevant studies. Third, only one author extracted
data. However, a second author checked all data extrac-
tion ﬁnding and reported very high percentage agree-
ment with the original data extraction ﬁndings. Fourth,
the tool used to assess the methodological quality of
included studies had not been tested for reliability and
validity. However, the tool reported substantial inter-
rater reliability agreement between blinded authors in
this study, had high face validity and aligned with items
Table 4 Pooled random-effects estimates for diabetes-related foot wound prevalence expressed as % (95% CI)
Study
Sample
size
Prevalence
estimates 95% CI
Percentage
weighting
Study quality
score
Asumanu et al40 966 4.3 3.1 to 5.6 14.60 5
Hurd and Posnett43 3099 1.1 0.7 to 1.5 18.99 6
Mahé et al45 624 0.5 −0.1 to 1.0 18.40 6
Mohammad Akther et al47 5188 1.1 0.8 to 1.3 19.22 5
Ogbera et al51 1327 2.7 1.8 to 3.6 16.84 4
Unachukwu et al55 827 7.0 5.3 to 8.8 11.95 4
Pooled estimate 2.4 1.5 to 3.4 p<0.001
I2 94.2% p<0.001
Table 5 Pooled random-effects estimates for diabetes-related foot infection prevalence expressed as % (95% CI)
Study
Sample
size
Prevalence
estimates 95% CI
Percentage
weighting
Study quality
score
Asumanu et al40 966 3.3 2.2 to 4.4 33.42 5
Mohammad Akther et al47 5188 0.6 0.4 to 0.8 34.82 5
Unachukwu et al55 827 6.4 4.7 to 8.1 31.76 4
Pooled estimate 3.4 0.2 to 6.5 p=0.037
I2 97.0% p<0.001
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reported to provide best practice methodological quality
assessments for observational studies.108 Lastly, the
pooled prevalence estimates calculated in this review
reported very high statistical heterogeneity, and some
may argue the value of reporting such heterogeneous
ﬁndings.29 However, the authors used conservative
random-effects meta-analyses models weighted on total
sample size in an attempt to account for heterogen-
eity.29 Furthermore, the authors consider the reporting
of heterogeneous pooled prevalence estimates, with the
clear cautionary notes provided by the authors on inter-
pretation, provide considerable additional value and
transparency to the existing literature available in this
ﬁeld.29
Interpretations of findings
The most consistent deﬁciency in study quality identiﬁed
in this review was that no studies reported CIs for foot
disease or risk factor prevalence ﬁndings. This was most
probably related to very few studies investigating a foot
disease disorder or risk factor as their primary outcome
of interest.24 32 36 37 41 42 47 49 50 52 83 106 107 Most studies
reported foot disease or risk factors as an additional aim
to the primary study aim of investigating the prevalence
of a larger condition, such as the total pressure ulcer or
diabetes prevalence. This lack of focus on foot disease
may have led to an under-reporting of prevalence ﬁnd-
ings as suggested in other similar studies.5 30 31
Furthermore, 7 of the 15 study cohorts that were investi-
gated primarily for a foot disease disorder or risk factor
were retrospective studies.24 36 49 50 52 Retrospective
studies have been found to also considerably under-
report prevalence compared with prospectively designed
studies utilising validated outcome measures,5 30 31 and
this also seemed to be the case in this review. Only eight
study cohorts were prospectively investigated for the
primary reason of identifying a foot disease disorder or
risk factor;32 37 40 42 47 83 106 107 however, only one used
an unbiased method of measurement.37 This particular
study investigated PAD using a reliable and validated
non-invasive ankle brachial index method.37 With nearly
all studies either retrospective in design or investigating
a foot disease disorder or risk factor as an additional
outcome, it could be hypothesised that the pooled
prevalence estimates reported in this review are likely to
underestimate the actual burden of foot disease in
inpatient populations.
Foot wounds were by far the most identiﬁed and
reported foot disease disorder arising from this system-
atic review. Yet, only three studies reported on all-cause
foot wound prevalence.24 34 35 A large retrospective
study by Currie et al24 investigating foot disease disorders
and risk factors when they were the primary reason for
admission was the only study with the primary aim of
investigating all-cause foot wounds and reported a foot
wound prevalence of 0.7%. The other two studies were
prospective studies and reported all-cause foot wound
prevalence of 1.6%34 and 4.2%,35 respectively. However,
the primary aims of these prospective studies were to
investigate wound prevalence, and thus, identifying foot
wounds was one of several additional aims investigating
different wound locations.34 35 Limitations in study
numbers and quality calls into question the precision of
all-cause foot wound prevalence estimates and meant
pooled estimates could not be calculated.
In contrast, the study numbers and quality were sufﬁ-
cient to perform meta-analyses on diabetes-related foot
wound and pressure ulcer-related foot wound preva-
lence. The increased numbers of studies reporting these
two condition-related areas is perhaps not unexpected
considering aspects of diabetes and pressure ulcer man-
agement are commonly utilised internationally as key
performance indicators of hospital care quality.4 109–112
Foot wounds are major contributors to poor outcomes in
both these conditions.4 38 63 101 110 The pooled preva-
lence estimates for diabetes-related foot wounds (2.4%)
and pressure ulcer-related foot wounds (4.6%) from this
review indicate these foot wounds do contribute consid-
erable burdens on the hospital inpatient system. While
there were more studies investigating these two
condition-related foot wounds in general inpatient popu-
lations again both pooled prevalence estimates had very
high heterogeneity. This may be attributed to only ‘mod-
erate’ study quality scores being eligible for inclusion in
the calculation of the diabetes-related foot wound
pooled prevalence estimate. However, this was not the
case for the pressure ulcer-related foot wound pooled
prevalence estimate where overall included study quality
scores were ‘good’. Interestingly, the only factor identi-
ﬁed in the scatterplots to bias pressure ulcer-related foot
wound prevalence ﬁndings was the bias of the investiga-
tors themselves. This suggests in studies where investiga-
tors or data collectors investigated participants from
their own hospitals pressure ulcer prevalence were
Table 6 Pooled random-effects estimates for diabetes-related foot disease prevalence expressed as % (95% CI)
Study
Sample
size
Prevalence
estimates 95% CI
Percentage
weighting
Study quality
score
Asumanu et al40 966 8.3 6.6 to 10.0 32.66 5
Daultrey et al42 810 4.9 3.4 to 6.4 33.05 4
Mohammad Akther et al47 5188 1.1 0.8 to 1.3 34.28 5
Pooled estimate 4.7 0.3 to 9.2 p=0.038
I2 97.8% p<0.001
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under-reported. As this was the only factor identiﬁed to
bias pressure ulcer-related foot wound prevalence from
this review, it is therefore plausible, that the variation in
pressure ulcer-related foot wound prevalence is largely
affected by the quality of care provided by the individual
hospital. Thus, this would support the ongoing use of
unbiased pressure ulcer prevalence as a key performance
indicator of hospital care quality.4 82 101
It was apparent that most studies reporting pressure
ulcer-related foot wounds did not exclude wounds of
diabetes origin, and conversely, most studies reporting
diabetes-related foot wounds did not exclude wounds of
pressure ulcer-related origin. This potential cross-
contamination suggests studies reporting pressure ulcer-
related foot wounds may inadvertently be a combination
of the prevalence of pressure ulcer-related and diabetes-
related foot wounds. Furthermore, literature reports
stage 1 pressure ulcers make up to 50% of the total pres-
sure ulcer burden.63 82 101 Stage 1 pressure ulcers are
deﬁned as non-blanchable erythema without skin loss or
a ‘pre-pressure ulcer’.63 82 This suggests the real pressure
ulcer-related foot wound prevalence in those inpatients
with skin loss may make up only 50% of the 4.6%
pooled prevalence estimate reported from this review.
Thus, it could be hypothesised that the real pressure
ulcer-related wound prevalence may be closer to 2.4%
pooled prevalence estimate ﬁndings for diabetes-related
foot wounds. Again considering the high likelihood of
cross-contamination of these two large condition-related
foot wound types, this hypothesis may extend to the sug-
gestion that pressure ulcer-related foot wounds with skin
loss could be a useful surrogate marker for all-cause foot
wound prevalence and a potential indicator of foot care
quality. However, these hypotheses need to be inter-
preted with much caution until further investigations
support its use in this capacity.
Foot infection was the other major foot disease dis-
order included in this review and was typically reported
to affect existing foot wounds.47 51 55 The retrospective
analysis by Currie et al24 was the only study primarily
investigating all-cause foot infection prevalence and
reported a rate of 0.5%. Another retrospective study to
primarily investigate foot infection reported a rate of
0.1%; however, this study only investigated foot osteo-
myelitis (bone infection).36 The remaining ﬁve cohorts
reported diabetes-related foot infections.24 40 47 55 56
The prospective pooled prevalence estimate for diabetes-
related foot infection was 3.4% (0.2–6.5); yet, statistical
heterogeneity was again high and needs to be inter-
preted with caution. This is particularly the case consid-
ering the pooled prevalence estimate for
diabetes-related foot infection was higher than for
diabetes-related foot wounds. However, the ﬁndings
from the three studies used to calculate the diabetes-
related foot infection pooled prevalence estimate each
individually found higher diabetes-related foot wound
prevalence than they did for diabetes-related foot infec-
tion prevalence.40 47 55
The aforementioned study by Currie et al24 was also
the only study to primarily investigate all-cause collective
foot disease prevalence in a general inpatient popula-
tion. This retrospective study analysed the proportion of
foot disease that were the primary reason for admission
from over 300 000 hospitalisations recorded in a Welsh
national hospital discharge data set.24 Interestingly, even
though the retrospective study design used in this large
study make signiﬁcant under-reporting likely,5 30 31 it still
identiﬁed that collectively foot disease was the primary
reason for admission in 1.2% of hospitalisations.24 Foot
disease was also collectively reported in 11 other study
cohorts with prevalence ranging from 0.2% to 11.9%.
However, a pooled prevalence estimate of
4.7%40 43 45 47 51 55 could only be calculated for
diabetes-related foot disease and this was again a hetero-
geneous ﬁnding. One factor that may have inﬂuenced
these high heterogeneous ﬁndings was the different
synonyms and inclusion criteria used to deﬁne collective
foot disease disorders between studies. The terms varied
between ‘foot disease’,40 ‘foot problems’,42 53 ‘diabetic
foot’38 41 and an aggregation of different foot disease
disorders.24 47 49 The inconsistency of terms, deﬁnitions
and the speciﬁc foot disease disorders included within
these collective ‘foot disease’ groups appears to be a
major contributing factor in the heterogeneity of these
ﬁndings. It is recommended that a formal international
consensus process is undertaken to determine an agreed
foot disease deﬁnition so as to allow clinicians and
researchers to compare homogeneous ‘foot disease’ out-
comes in future.
The major risk factors for foot disease included in this
study were PAD, PN and foot deformity. PAD was the
most reported risk factor in 10 cohorts. Two
‘moderate-to-good’ quality prospective studies of all-
cause PAD using similar gold standard non-invasive vas-
cular outcome measures reported similar 29.6% and
36.0% prevalence ﬁndings.32 37 In contrast, other PAD
studies were either retrospective in design or reported
PAD using a non-valid or reliable method. However, the
methodological deﬁciencies of these studies translated
to poorer study quality scores and much lower PAD
prevalence ranges of 0.01–0.5%. Thus, using the most
robust study quality evidence available, it could be
hypothesised that PAD is present in approximately
one-third of general inpatient populations.32 37 PN was
reported in six cohorts with the only study reporting all-
cause PN prevalence (0.2%) again the retrospective
study by Currie et al.24 All other studies reported
diabetes-related PN prevalence ranging from 0.003% to
2.8% in general inpatient populations.24 40 44 48 52 The
only study to primarily investigate diabetes-related PN
identiﬁed that 2.8% of all inpatients had diabetes-related
PN using a validated tool.40 However, with only one
retrospective study reporting all-cause PN and all other
studies reporting condition-related PN, these low
reported PN prevalence rates could again be considered
to under-report the actual all-cause PN prevalence in
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inpatients. Foot deformity was not identiﬁed by this
review. Unfortunately, there were insufﬁcient studies of
satisfactory quality to enable the calculation of a pooled
prevalence estimate for any risk factor. Therefore, until
further studies are conducted, the best estimate of the
proportion of general inpatient populations with a
major risk factor for foot disease appears to be up to
36%.32 37
Lastly, amputation prevalence was reported in 10
included study cohorts identiﬁed by this review ranging
from 0.03% to 1.5%.24 33 36 40 46 48 55 50 The only study
primarily investigating all-cause amputation in this
context was again the retrospective study by Currie
et al24 suggesting 0.1% prevalence in general inpatient
populations. Most remaining studies reported diabetes-
related amputation rates which ranged between 0.04%
and 1.5%.24 33 40 46 48 55 50 Unfortunately, there were
insufﬁcient studies to calculate a pooled prevalence esti-
mate. However, this prevalence range may not be
exhaustive and needs to be interpreted with caution, as
amputation was a secondary aim of this review and only
reported from studies that also reported foot disease or
risk factors.
Implications for clinicians, researchers and policymakers
While reviews have been investigating the inpatient
burden of major organ disease for some time, such as
heart disease,113–115 this appears to be the ﬁrst review to
determine more precise estimates for foot disease in
general inpatient populations. This review has identiﬁed
that foot disease is present in considerable proportions
of the general inpatient population. Primary ﬁndings
indicate 1 in 20 inpatients had foot disease and 1 in 3
inpatients had a major risk factor for foot disease. This
review also supports existing evidence suggesting foot
disease is present in large proportions of discrete
inpatient populations, such as patients with diabetes1–3
and pressure ulcers.4 82 101 Furthermore, additional ﬁnd-
ings indicate 1 in every 100 inpatients had been hospita-
lised because of foot disease and up to 1.5% of all
inpatients were in hospital to have an amputation pro-
cedure. Although pooled prevalence estimates in this
review had high heterogeneity, they are the most precise
prevalence estimates to date to quantify the burden of
foot disease present in general inpatient populations.
Overall ﬁndings from this review appear to be very likely
an underestimate of this burden.
With such a considerable proportion of foot disease
present in inpatient populations, it is perhaps surprising
that more research has not been conducted to primarily
investigate this potentially considerable burden.
However, this review does highlight the need for clini-
cians, researchers and policymakers to better understand
and address this seemingly under-recognised burden in
inpatient populations. It is recommended that future
studies in this ﬁeld should be prospective in design,
have a primary aim to investigate foot disease in
inpatient populations and use unbiased, reliable and
validated foot disease and risk factor outcome measures.
Furthermore, it is recommended the ﬁndings of this
review should inform policy to more precisely address
this under-recognised yet considerable burden of foot
disease in inpatient populations.
CONCLUSIONS
This is the ﬁrst known systematic review to synthesise the
literature on foot disease in inpatient populations and
provides the best estimates to date of this burden.
Findings from this review indicate up to 36% of all inpa-
tients had a major risk factor for foot disease, 5% had
foot disease and up to 1% were in hospital because of
foot disease. Owing to the high heterogeneity of
included studies, these estimates need to be interpreted
with caution; however, they are more likely to under-
report the inpatient foot disease burden. This review
highlights the urgent need for further research to more
robustly quantify, and address, what appears to be a con-
siderable burden of foot disease present in general
inpatient populations.
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